Production of retroviral vectors for clinical use requires removal of cells and cellular debris. We combined a series of filters of decreasing pore size using commercially available blood banking filters approved for clinical use. The collection bag and filters can be connected to create a sterile, closed system using clinically approved tubing and sealing systems. Even when challenged with a large number of vec-
Introduction
Generation of retroviral vectors for clinical trials requires methodologies which increase production volume while maximizing titer of the manufactured product. One challenge in processing vector is efficient removal of cells and other debris without significantly decreasing titer. To obtain cell-free material, investigators have utilized filter systems ranging from 0.2 to 0.45 micron pore size which are commercially available and well suited for use in processing small to moderate volumes of vector supernate (less than a liter). Unfortunately, these systems are known to decrease titer and are not well suited to larger filtration volumes (liters). We hypothesized that a series of filters with decreasing pore sizes may provide more rapid filtration than single pore size filters and would also improve recovery of vector particles yielding higher titer of the manufactured material. To this end, we evaluated a step filtration system for processing large volumes of supernate. The components of this system are filtration devices currently approved for clinical use and used routinely in blood banking. The components can be joined using a sterile connecting device to form a closed system decreasing the risk of contamination. For vector production runs in excess of 2 liters, our analysis indicates this system provides cell-free material of higher titer and at lower cost than filtration through 0.45 filters.
Results and discussion
We hypothesized that filtration through a series of filters of decreasing pore size ( Figure 1 ) may decrease filtration tor producer cells (2.38 × 10 9 cells), no viable cells are passed through the system. The step filtration system developed minimizes the titer reduction associated with filtration, provides rapid flow rates, and was cost effective when filtering volumes in excess of 2 liters. Gene Therapy (2000) 7, 1993-1998. Figure 1 Step filtration system. Supernate is collected into a blood transfer pack then passed through a dual in-line filter with 40-and 150-pores, followed by filtration through a 20-filter. The final filter is a Sepacell filter used for leukocyte reduction. The product is collected into one or more 2 liter transfer packs before distribution into Cryocyte freezing bags. The filtration system is connected using the Terumo Sterile Connecting Device with welding wafers.
time by removing large debris before it can obstruct filtration through small pore filters. Unobstructed filters should generate less shear forces, allowing higher flow rates, quicker freezing, and result in higher titer of the final product. To test this hypothesis, we compared the titer obtained after step filtration with filtration through a 0.45-filter. Forty-five roller bottles (Corning, No. 421198) were seeded with AM12-MSCV2.MGMT retroviral producer cells and propagated to confluence at 37°C, 5% CO 2 . One day after confluence, the temperature was dropped to 32°C and the medium was changed. We had previously determined that maximal titer production occurred when confluent roller bottles of this vector were harvested at 8-h intervals.
1 Sequential harvests were performed and the titers obtained are shown in Figure 2 . At optimal harvest conditions for this vector, we noted a median 8.6-fold higher titer when supernate was filtered through the step filtration system compared with filtration though a single 0.45-filter. Based on this encouraging preliminary result, we began a series of experiments to further characterize this filtration method.
It should be noted that both filtration methods will decrease titer compared with unfiltered material. The titer from unfiltered supernate was compared with material passed through a 0.45 filter or treated by the step filtration method. Supernate was obtained from five sequential harvests from a roller bottle production of the PG13/LN clone 8 retroviral vector. Unfiltered material from harvests 1, 3 and 5 were analyzed and had a titer of 1.35 ± 4.1 (s.e.) × 10 To ensure the test filtration system provided a cell-free product, three vector production runs were processed through the filtration system and tested for contaminating producer cells. After completion of the clinical production run (ie at the time of maximal cell density), fresh medium was added to each roller bottle and allowed to incubate for 24 h. The supernate was then harvested, passed through the filtration system, centrifuged in 250 ml conical tubes (250 g for 10 min) and the lower 30 ml was collected and placed in tissue culture flasks for 14 days. Flasks were then examined for the presence of colony formation. As shown in Table 1 , no producer cells were detected in the filtered product. Unfiltered supernate yielded 48 macroscopic colonies per liter.
To provide a more vigorous test of the filtration system, the filters were challenged with a suspension of producer cells in increasing increments. As shown in Table 2 , the challenge consisted of 250 ml of cell suspension beginning at 10 4 cells per ml and increased to a final challenge volume of 250 ml with a cell density of 10 7 cells per ml. This represents a total cell challenge of 2.78 × 10 9 cells. After filtration, the material was placed into flasks and cell growth was evaluated after 14 days. No cells could be recovered from the filtered supernate. We also determined that a roller bottle culture contains approximately 4 × 10 8 cells, and 50 roller bottles are used in a typical 3 liter harvest (total cells per harvest: 2 × 10 10 ). Therefore, our experiment indicates that even if 10% of cells were to become non-adherent, the step filtration system will still provide a cell-free vector product.
Another technical challenge for any filtration system is expeditious processing, since delays in freezing harvested supernate may decrease titer. One limitation of the single step filtration method is the tendency for decreased flow rates over time. To evaluate flow rates, five sequential harvests from a roller bottle production of Figure 3a illustrates the filtration times for the five harvests and demonstrates an initial rapid rate which significantly decreases as further material is filtered. Three of the filtered products decreased to flow rates less than 50 ml per 10 min, one of which decreased to zero before 200 ml of the product was filtered. If the harvested material was placed directly on the filtration unit without centrifugation, less volume can be filtered before the flow rate decreases and three of the five harvests failed to filter 200 ml before the filtration rate fell to zero (data not shown). This observation suggests that cell and cellular debris can obstruct 0.45-filters and while centrifugation before filtration improves flow rates, for most retroviral vector products the capacity of the filter is less than the 250 ml volume proposed by the manufacturer.
To evaluate the flow rate of the step filtration method, we recorded the flow times during a cell challenge. Even when the system was challenged with a total of 2.78 × 10 9 producer cells, the flow rate through the filter system was not significantly decreased ( Table 2) . To determine if similar filtration rates would be observed during a clinical production, we recorded the filtration time (including removal of material from roller bottle, introduction into the closed filtration system and filter time) for a total of 12 3-liter harvests using two vectors (five harvests of the PG13/LN⌬NGFRhutat2 and seven of the PG13/LN⌬NGFR vector). The mean time for filtration was 56.5 ± 3.5 s.e. min (range 35-80, median 55). The mean flow rate was 53 ml per minute. The flow rate for the step filtration system is an overestimation of the actual filtration time since the limiting step was often the ability to transfer material from the roller bottle to the filtration system.
Not unexpectedly, filtration rates correlated with the titer of the filtered material. The columns in Figure 3 illustrate the titer obtained in consecutive 50 ml pools of 0.45-filtered material for three production harvests. In harvest 3, the titer was relatively stable throughout filtration and the filtration was completed in 16 min. For harvests 1 and 5, the titer of the end material fell as the flow rate decreased, material obtained after 20 min of filtration appears to be five-fold lower in titer than material obtained during rapid filtration. The identical analysis was performed on material that was added to the 0.45-filter without prior centrifugation and the fall in titer was more rapid and of greater magnitude (data not shown). This fall in titer was not seen when using the step filtration method. Harvests of PG13/LN clone 8 supernate analyzed after 0.45-filtration were also analyzed after step filtration. As shown in Figure 4 , the lowest titer was noted in the first 5 ml filtered, but by 50 ml of filtered material the titer was similar to the median titer obtained for the remaining product and did not appear to decrease significantly at the higher volumes.
The decrease in titer associated with poor flow rates of 0.45-filters can be related to degradation of the vector, which is time dependent, or due to other factors. As shown in Table 3 , 0.45-filters yield similar titers when the flow rate is high. Specifically, when the titer of the filtered material is measured in the first 30 ml passed though a 0.45-filter the results are similar to titers obtained when 2-3 liters of material is filtered through Gene Therapy 
.45-filter was recorded for the five harvests at intervals of 50 ml of filtered product. Flow rates decreased over time and one product failed to filter within 60 min (harvest 2). (b) The titer of filtered material was determined for harvests 1, 3 and 5. Fifty-ml aliquots were collected and titered for G418 resistant colony-forming units on HeLa cells, the volumes collected are depicted in the legend to the right of the graph. Triplicate titer assays were performed for each sample. Bars indicate the standard error of the mean.
the step filtration system. The subsequent loss of titer as additional material is filtered through a 0.45-filter could be related to the known decay of vector particles that is both time-and temperature-dependent. When we evaluated the titer of vector supernate maintained at room temperature or 4°C and titered at times 0, 1, 2, 4 and 8 h, a significant decrease in titer was not observed for the first 4 h (data not shown). Since all processing was performed within this time-frame, other factors appear responsible for the loss in titer seen with 0.45-filters. Most likely, mechanical disruption of the vector as it passes Gene Therapy through obstructed filter pores is the major factor contributing to the loss of titer. We have observed that the relative benefit of step filtration is cell line-dependent. While most producer cell lines submitted to the NGVL are based on NIH3T3 cells, we have shown that the parent cell lines and the derived vector producer cell lines differ significantly in terms of growth characteristics.
Figure 4 Vector titer after step filtration. The neomycin phosphotransferase gene containing vector LN clone 8 was generated in the PG13 cell line by roller bottle production (the same material was used to generate data presented in Figure 3). Five sequential harvests were performed, collecting supernate every 24 h. Harvests 1, 3 and 5 were used for this analysis. A total of 2.5 liters were filtered by step filtration and aliquots removed after the volumes (ml) specified in the legend. Five-ml aliquots were collected and titered for G418 resistant colony-forming units, the volumes collected are depicted in the legend to the right of the graph. The collected material was titered for G418 resistant colony-forming units on HeLa cells. Triplicate titer assays were performed for each sample. Bars indicate the standard error of the mean.
1 Vector producer cells release a variety of molecules and debris into the supernate, some of which can affect vector titer. 2 We have also observed that the ease with which products filter through a 0.45-filter varies from cell line to cell line. For those products which pass relatively rapidly through the 0.45-filters (such as PG13/LN clone 8, Figure 3) , the benefit from step filtration is modest, about two-fold. For products which filter slowly (such as GP+envAM12/ MSCVneoMGMT, Figure 2 ), step filtration markedly improves titer.
At our institution, the costs of filtering 3 liters of supernate using 0.45-filters (including pipettes, pooling flask and 20 filters) is $602. Disposables for the step filtration system are $454.60. Even without an improvement in titer, the step filtration system is cost-effective when producing volumes of supernate over 2 liter. Given that the titer obtained with step filtration is two-to eight-fold higher than 0.45-filters, additional saving is realized in the quality of the product generated.
Production of viral vectors suitable for human use is an evolving science where much work remains to define optimal production conditions. 3 Generation of clinical grade retroviral vectors by academic centers must balance efforts to maximize titer with the cost of production. For phase I trials submitted to the NGVL, the amount of material requested ranged from 10 to 40 liters of unconcentrated supernate. While bioreactors suitable for very large vector productions can increase titer, 4 the amount of cell debris from roller bottle systems may pose an even greater challenge for single filtration methods and suggest our step filtration method may provide added benefit to this method of manufacturing. Concentration and purification methods for vectors can also provide a product with increased titer 5, 6 and may eliminate the need for filtration. 7, 8 Unfortunately, the fragile state of the retroviral vectors results in loss of particles during concentration so the actual yield of vector particles is much lower than the amount produced, adding significant cost to production. While improved vector production technology is needed, generation of vector from producer cell lines by the methods described above are still likely to be utilized for many phase I studies. This is related in part to the cost advantages, and to recent improvements in transduction methodology allowing clinically significant transduction of target cells with unconcentrated retroviral vector. 9, 10 In summary, removal of cells and debris from vector supernate using a step filtration system improves titer and provides for a closed system which easily handles large volumes. Cryopreservation bags used for bone marrow storage provide for easy collection and storage of filtered material and are available in a variety of sizes, so the storage volume can be customized to meet the needs dictated by the intended clinical use.
Materials and methods

Filtration systems
Two methods of filtration were evaluated. The control method utilized 0.45-filtration flasks (product number 1530045, Nalgene, Rochester, NY, USA). Pooled supernate was transferred into the flasks by pipette and processed by vacuum-assisted filtration (maximum volume 200 ml per filter unit). The test method, a step filtration system, is shown in Figure 1 . Supernate was pooled into a bone marrow collection kit (product number 4R2107, Baxter, Deerfield, IL, USA) which has a capacity of 1. 
Media and cell culture
Murine cell lines were maintained in D10 media (high glucose Dulbecco's modified Eagle's medium with 10% fetal bovine serum (Hyclone, Logan, UT, USA), supplemented with 2 mmol/l glutamine, and 1 mmol/l Na pyruvate), and incubated at 37°C, 5% CO 2 . HeLa cells were maintained in MEM with Earle's salts, 10% fetal bovine serum, and 1% non-essential amino acids (Gibco, Grand Island, NY, USA). Vector producer cell lines utilized PG13 cells 11 and PA317 cells 12 obtained from the ATCC (Nos CCL-92, CRL-10685, CRL-9078, respectively). The GPE+86 13 and GPenvAm12 cell lines 14 were supplied by Genetix Inc (Tarrytown, NY, USA).
Drug resistance titer
Retroviral producer cell lines containing a drug resistance gene were assayed for vector titer by colony forming assay. 1 × 10 5 cells (NIH 3T3 for PA317 and GPenvAm12 packaged vector or HeLa cells for PG13 packaged vector) were plated in 60-mm 2 dishes. The following day vector samples were thawed, serial dilutions were prepared in triplicate (using D10 media) and target cells were transduced with 1 ml of vector-containing medium. The cells were incubated for 4 h at 37°C, 5% CO 2 in the presence of polybrene (8 g/ml), after which time the vector-containing medium was removed and replaced with fresh serum-containing medium. After 48 h, vector-transduced cells were incubated with serum-containing medium and the appropriate selection agent, either 750 g/ml of active G418 (Life Technologies) or 500 g/ml of Hygromycin B (Boehringer Mannheim, Indianapolis, IN, USA). After 10 days of culture, drug resistance colonies were scored and the colony-forming units per milliliter of vector supernate was calculated.
Roller bottle cultures A variety of vectors submitted to the NGVL for clinical grade production were tested for the optimal time for harvesting vector supernate. For clinical production and other roller bottle productions used in this analysis, a Forma incubator (Model No. 3956, Marietta, OH, USA) was used with a Wheaton roller bottle unit (No. 348940/348949, Wheaton Science Products, Millville, NJ, USA). Cells from a single pool of cells are seeded in 850-cm 2 bottles (Corning No. 431198, Corning, NY, USA) at a rotation speed of 5-10%. Rotation speed is increased after 12-24 h to 20%. Cultures are grown with 60 ml of medium and harvested when confluent. Glucose is monitored after each sequential harvest and for clinical production the volume is increased to 120 ml when the harvest glucose falls below 200 mg/dl (titer is volumedependent and optimal titer at the initiation of sequential harvesting is obtained at 60 ml, data not shown).
Titer assessment by flow cytometry Ecotropically packaged MFG-eGFP vector, which expresses the enhanced green fluorescence protein (GFP), 15 was used to generate MFG-eGFP vector producer cells in the PA317 and PG13 cell lines. Vector expressing producer cells were obtained by cell sorting using a FACStar Plus (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA). Titer was assessed by determining the transduction efficiency of target cells. Undiluted supernate (1 ml) was incubated with 1 × 10 5 target cells (NIH 3T3 cells for MFG-eGFP/PA317 cells or HeLa cells for MFG-eGFP/PG13) per well of a six-well dish approximately 16 h after plating. Cells were exposed to undiluted and 1:10 diluted vector for 4 h in the presence of 8 g/ml polybrene (5% CO 2 , 37°C). Cells were maintained in culture for 2-3 days then trypsinized, washed twice in phosphate-buffered saline, and analyzed for fluorescence using a FACScan (Becton Dickinson Immunocytometry Systems).
